by Mark Chiang

马克·江

Share To

分享到

Ambience Healthcare has secured $243 million in new funding, raising its valuation to $1.25 billion. The announcement was made on Tuesday, marking a significant milestone for the company and contributing to a broader trend of substantial investments in AI-powered medical transcription technology this year..

Ambience Healthcare 已获得 2.43 亿美元的新资金，使其估值达到 12.5 亿美元。这项公告于周二发布，标志着该公司的一个重要里程碑，并推动了今年在人工智能驱动的医疗转录技术领域的大量投资趋势。

The latest funding round adds to nearly $1 billion raised collectively by companies specializing in AI-driven scribe solutions since the beginning of 2025. Ambience Healthcare’s valuation reflects growing interest in artificial intelligence applications aimed at streamlining administrative tasks within healthcare settings.

最新一轮融资使自2025年初以来，专注于人工智能驱动的书记解决方案的公司总共筹集的资金接近10亿美元。Ambience Healthcare的估值反映了人们对旨在简化医疗环境中行政任务的人工智能应用越来越感兴趣。

These technologies are designed to assist clinicians by automating documentation processes, potentially reducing workloads and improving efficiency..

这些技术旨在通过自动化文档处理过程来帮助临床医生，可能会减轻工作量并提高效率。

Newsflash | Powered by GeneOnline AI

新闻快讯 | 由GeneOnline AI提供支持

Source: GO-AI-ne1

来源：GO-AI-ne1

Date: July 29, 2025

日期：2025年7月29日

Related posts:

相关文章：

DrugPatentWatch: Data Analysis Could Cut Pharma Patent Litigation Costs by 50%

DrugPatentWatch：数据分析可将医药专利诉讼成本降低50%

Federal Equipment Company Implements Training and Auction Strategies to Support CDMOs in Pharmaceutical Manufacturing

联邦设备公司实施培训和拍卖策略以支持CDMO在制药生产中的发展

European Commission Approves SYD-101 for Paediatric Myopia Treatment Across EU

欧盟委员会批准SYD-101用于欧盟范围内小儿近视治疗

Cilta-cel Therapy Achieves Sustained Remission in CARTITUDE-1 Trial for Relapsed Multiple Myeloma

Cilta-cel疗法在CARTITUDE-1试验中实现了复发性多发性骨髓瘤的持续缓解

©www.geneonline.com All rights reserved. Collaborate with us:

©www.geneonline.com 版权所有。与我们合作：

[email protected]

[email protected]

Author

作者

Mark Chiang

马克·蒋

Related Post

相关文章

News Flash

新闻快讯

South Korea’s Biopharmaceutical Licensing Deals Reach $7.86 Billion in 2025 YTD, Up 113% from Last Year

韩国生物制药许可交易额2025年迄今达78.6亿美元，同比增长113%

2025-07-29

2025年7月29日